The Studies ...

Few questions around the release of results from the clinical studies, as per my understanding from the 2 March "Lunch and Learn" presentation.

3 April - Decision as to whether SIRFLOX/FOXFIRE/SIRFLOX Global is granted a presentation slot at ASCO
3 April - Decision as to whether SIRveNIB is granted a presentation slot  at ASCO

Question:  If either or both of these clinical studies is not granted presentation slots at ASCO, does this effectively guarantee that the studies have failed to achieve primary and secondary endpoints?

Question:  If the studies are not granted presentation slots at ASCO, will Sirtex be able to release trial results on this day?



5 April - SARAH Abstract release (unless embargoed)

Questions - What would be a reason for an embargo?  What would an embargo imply (if anything) about the trial results?




Question - Is it safe to assume that achievement (or otherwise) of all primary and secondary endpoints for a trial are revealed when an abstract is released?

Thanks in advance to anyone who can shed light.